A New Tri-functional Product has arrived in South Africa

Innovation is a way of life

For us at Glenmark, innovation is not just a term, referring to scientific research and discovery.

It’s a way of life, it’s a means of creating a healthy, happy, ailment-free world.

All our actions are guided by innovative thinking and a strong set of values.

We practice innovation by finding new ways of doing things – big or small, thereby enabling us to enrich the lives of people across the globe.

Our R&D centers deliver innovation by combining cutting-edge technology, state-of-the-art infrastructure, and the brightest minds in the business.

Glenmark has its NCE, BioPharmaceutical, Clinical and Generics R&D center in India, Switzerland, and the US.

Glenmark’s R&D team of over 800 members is committed to discovering new possibilities for a better world.

Glenmark South Africa continues to work towards extending, developing, and focusing on its Dermatology Portfolio that has an integral role in developing medically niched support for the insights and the foresight of Dermatologists and skincare specialists in South Africa.

With all that said, Glenmark South Africa is proud to announce the:

1st to Market Generic of Imiquimod

Glenmark Dermatology

Glentriz TM launch
SBCC's. Warts. AKs
Glentriz wart reduction
Bioequivalence

Glentriz™ is indicated in the treatment of:

  • External genital / Perianal warts (condyloma acuminata) in adult patients

  • Clinically typical, non-hyperkeratotic, non-hypertrophic actinic keratosis (AKs) on the face or scalp in adult patients

  • Topical treatment of superficial basal cell carcinoma (sBCC) in adult patients

Glentriz advert

External Genital Warts (EGW)

  • External genital warts

    Glentriz™ (imiquimod 5%) first-time recommendation by 14 global Anogenital wart experts

  • External genital warts

    Worldwide approved for the treatment of EGW

  • External genital warts

    Glentriz™ is as effective and safe as originator cream in the topical treatment of patients with external genital warts

  • External genital warts

    Clearance rates for ECW with Glentriz™ 35-75%

  • External genital warts

    Imiquimod was rated better in terms of overall satisfaction, convenience, time to clearance, and lack of associated pain than other EGW therapies

Actinic Keratosis (AK)

  • Aktinic Keratosis

    Reflectance confocal microscopy(RCM) studies have shown that field therapies such as imiquimod, can clear subclinical lesions

  • Aktinic Keratosis

    Guidelines for the Treatment of Actinic Keratosis

  • Aktinic Keratosis

    In patients with single AK lesions

  • Aktinic Keratosis

    In patients with multiple AK lesions

  • Aktinic Keratosis

    For immunocompromised patients with AK

  • Aktinic Keratosis

    Cosmetically superior to cryotherapy

  • Aktinic Keratosis

    Excellent cosmetic outcome reported

  • Aktinic Keratosis

    Better skin appearance reported

Superficial Basal Cell Carcinoma (sBCC)

  • Superficial Basal Cell Carcinoma (sBCC)

    Basal cell carcinoma (BCC) accounts for 80% of all skin cancers

  • Superficial Basal Cell Carcinoma (sBCC)

    Incidence BCC is increasing worldwide by up to 10% annually

  • Superficial Basal Cell Carcinoma (sBCC)

    Imiquimod has been used as a good alternative for surgery in sBCC
    In 4256 patients with sBCC imiquimod 5% compared to other treatments:

  • Superficial Basal Cell Carcinoma (sBCC)

    Superior composite cure rate (p=0,0011)

  • Superficial Basal Cell Carcinoma (sBCC)

    Significantly greater complete response rate with imiquimod (p=0,001)

  • Superficial Basal Cell Carcinoma (sBCC)

    Significantly superior histological cure rate (p<0,001)

Join us for the Skin Cancer Clinical Overview Educational Webinar

Skin Cancer Clinical overview
Keynote Speaker

Dr Irshad Essack
MBChB (Natal) FCDerm (SA)

Topic: Skin Cancer
Clinical overview of Actinic Keratosis and NMSC
Sunday, 24 October 2021 11:00 – 15:30 (GMT+2)

Read More
Dr Irshad Essack

Want to know more about Glentriz™ and Glenmark?

Meet with Karlo Mitchell

Book a meeting with Karlo Mitchell

Glenmark Pharmaceuticals South Africa

Glenmark Dermatology

Glenmark Pharmaceuticals South Africa (Pty) Ltd was launched in December 2005. The company has been based in Midrand, Johannesburg since its inception. What started as a smaller organisation with only seven employees has now grown to be a productive, innovative company with more than 40 employees.

Since October 2018, Glenmark South Africa, under new and experienced leadership, has seen numerous promising developments in its existing and future portfolio, both in the dermatology and respiratory areas.

Expanding on the company’s specialty in the dermatology arena, Glenmark South Africa is pleased to announce that they are the first company to launch a generic Imiquimod Cream (5 %) in South Africa. This marks the 1st of a very strong dermatology pipeline to follow in the coming years.

Connect with Glenmark Pharmaceuticals

Address: 2nd Floor, Building D, Stoneridge Office Park, 8 Greenstone Place, Greenstone, Edenvale, Gauteng, 1609
Phone: +27(0) 11 564 3900
Fax: +27(0)86 600 6128